Prognose

Das durchschnittliche Kursziel der Analysten beträgt +6,22€(+19,62%). Der Median liegt bei +5,94€(+14,23%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.» Mehr auf zacks.com
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). The collaboration harnesses Noetik's proprietary virtual cell foundatio.» Mehr auf businesswire.com
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- #aiinbiotech--Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology.» Mehr auf businesswire.com

Im letzten Quartal hatte Agenus Inc. einen Umsatz von 22,25 Mio€ und ein Nettoeinkommen von −23,40 Mio€